《大行報告》瑞信昇華晨(01114.HK)評級至「跑贏大市」 指華晨寶馬上季盈利創新高
瑞信發表報告指,寶馬集團今年第三季業績表現顯示,期內華晨中國(01114.HK)與寶馬合資公司的盈利創歷史新高,達103億元人民幣,按年增長43%(按季增長102%)。由於半導體供應的改善,合資公司銷量按年增長21%,按季則增長16%,另外,公司第三季的淨利潤率亦有改善。
該行表示,考慮到寶馬合資公司的利潤率勝於預期,將華晨中國今明兩年的每股盈利預測分別上調7%和3.3%,對華晨中國目標價從7.8元上調至8元。
瑞信指,由於該行對寶馬合營企業的銷量假設較低,將其2024年每股盈測略微下調3%。同時,由於集團復牌後股價大幅下跌,因此,將華晨的投資評級由「中性」上調至「跑贏大市」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.